In the late 1950s, a West German company called Chemie Grünenthal was selling a sedative called thalidomide under the brand name Contergan. The pitch was simple and powerful: unlike barbiturates, which could kill you in overdose, thalidomide appeared almost impossible to take a lethal dose of. It was safe. It was gentle. It was exactly what the market wanted.
Clinicians noticed it worked well for pregnancy-induced nausea. So it got marketed directly to pregnant women. Millions of strips were sold across Europe, Australia, Canada, and South America. At the time, there was no requirement to test what a drug did to a developing fetus before putting it on the shelf. Nobody asked that question formally. Nobody mandated an answer.
That gap killed over 10,000 children.
The drug that seemed too safe to question
The selling point for thalidomide was its safety profile. In animal testing, researchers could not establish a lethal dose — the drug appeared to have an almost unlimited ceiling before toxicity. For a market used to barbiturates, where an accidental overdose could stop a person's breathing, this was genuinely valuable. A sedative you could not kill yourself with, available over the counter. The demand was real.
What nobody tested — and what no law at the time required anyone to test — was what the drug did to a developing fetus. The science to ask this question existed. The 1940s had already demonstrated that specific chemicals could cause birth defects in mammals through maternal exposure. The question was askable. It was simply not mandatory before commercial launch.
What happened in delivery rooms
By the late 1950s, something was going wrong in hospitals across Europe. Obstetricians were seeing a surge in phocomelia — a congenital condition where a baby is born with severely shortened or completely absent limbs, along with ear deformities, eye defects, and heart abnormalities. It was a deformity so rare that most doctors had never seen a single case in their careers. Suddenly, it was appearing in clusters.
By late 1961, researchers independently connected the pattern to thalidomide. The window of vulnerability was shockingly narrow — exposure between gestational days 20 and 36 was enough. Day 24, and upper limb development was at risk. Day 28, and lower limbs. Most women did not even know they were pregnant when that window opened.
A single tablet taken between gestational day 20 and 36 was sufficient to cause life-altering birth defects. Day 20–24 caused ear malformations. Day 24–33 caused upper limb phocomelia. Day 28–36 targeted lower limb development. This window opens before most women have confirmed a pregnancy.
The drug was withdrawn globally in late 1961 and early 1962. The damage was already done — over 10,000 children born with thalidomide embryopathy, many with conditions that would require a lifetime of support.
The woman who said no
While Europe and the Commonwealth were dealing with the fallout, the United States largely escaped. Not because the system was better designed — because of one person inside it.
When Richardson-Merrell applied to distribute thalidomide in the US under the brand name Kevadon in 1960, the application landed with Dr. Frances Kelsey, a newly appointed FDA medical officer. The manufacturer expected a routine sign-off based on extensive European sales data.
Kelsey felt the toxicological data was incomplete. The European files did not prove the drug could not cross the placental barrier. She had also seen the European reports on peripheral neuritis — nerve inflammation in long-term users — which nobody had adequately explained. The manufacturer pressured her repeatedly. She held the application anyway.
Kelsey did not have better data than the Europeans. She had higher standards for what data she would accept before signing off. That difference prevented thousands of cases in the United States.
By the time the European birth defect data emerged, the US had not approved the drug. Her decision — to treat incomplete safety data as insufficient, not merely as pending — is the model that modern drug reviewers are trained on.
The Indian chapter nobody talks about
The standard telling of the thalidomide story treats India as irrelevant — the drug never arrived, no harm was done, move on. The reality is more complicated, and understanding it matters for anyone working in Indian pharma regulation.
Mainland India did block thalidomide. The drug control authority required formal registration of imported drugs, and Grünenthal could not navigate the bureaucratic requirements quickly enough before the global withdrawal. Commercial distribution never officially commenced on the mainland.
But Goa was not mainland India in 1959. It was a Portuguese colony — a separate legal enclave where the registration of foreign drugs was not required. In November 1959, three thalidomide formulations arrived in Goa through a local distributor called Drogaria Raicar. A sales force was trained and deployed to pitch these products to local doctors. The colonial pipeline ran until December 1961, when Indian troops integrated the territory.
The reason no confirmed cases of thalidomide-induced phocomelia were ever documented in India is straightforward: the total volume of active substance shipped into Goa during that window was approximately 2.2 kilograms. A small market, a short window, and no surveillance system that would have caught it anyway. The protection was geographic and accidental, not regulatory.
When the Indian government did respond, in July 1962, it quietly amended the Drugs Rules of 1945 to place thalidomide on prescription and poisonous substance schedules. The Deputy Health Minister announced to the Lok Sabha that an import licence application had been cancelled due to overseas toxicity reports. The official line was that no commercial consignments had landed. That was true for the mainland. It was not the whole story.
What changed permanently
The Kefauver-Harris Amendments of 1962, passed by the US Congress in direct response to the crisis, restructured drug approval standards globally. For the first time, manufacturers had to prove a drug was both safe and clinically effective before it could be marketed. Teratogenicity testing — multi-generational animal reproduction studies to evaluate birth defect risks — became mandatory worldwide. Informed consent in clinical trials became a legal requirement. Adverse event reporting became compulsory.
Before 1962, the question regulators asked was: is this drug pure and is it acutely toxic? After 1962, the question became: does it actually work, and what does it do to a fetus? That is the framework every drug in the world is approved under today. The CDSCO process, the DCGI requirements, the clinical trial rules in India that a B.Pharma student learns — all of it traces back to the regulatory vacuum that thalidomide exposed.
The unexpected second act
Thalidomide was not finished. In 1964, an Israeli dermatologist named Jacob Sheskin discovered that thalidomide given to leprosy patients with a severe inflammatory complication called Erythema Nodosum Leprosum cleared their lesions and fever within 48 hours. A drug that had caused birth defects in thousands was now relieving pain in people with no other options.
This mattered enormously for India, which carried more than 54 percent of the world's leprosy burden through the 1960s to 1990s — between 60,000 and 300,000 acute ENL cases annually. The drug was not officially licensed, but it began re-entering India through humanitarian channels managed by NGOs like the German Leprosy Relief Association. Indian specialists were part of formal international symposiums on the topic from 1966. By late 1966 it was in active use at leprosy hospitals in Mangalore.
Grünenthal itself shipped tablets free of charge and advised on dosing protocols — including a documented statement that they had no objection to giving the drug to women of childbearing age as long as clinicians were not certain a patient was pregnant. That sentence is worth sitting with. The same company that had distributed a teratogenic drug without adequate safety data was now advising on its use in a country with limited surveillance, recommending it be given to women who might be pregnant, as long as pregnancy was not confirmed.
In 1986 the Indian government formally assumed control of distribution to leprosy clinics. In 2002, the CDSCO granted the first official marketing licences — for ENL and multiple myeloma, where thalidomide's anti-angiogenic properties cut off blood supply to tumour cells. India is now a leading global exporter of next-generation thalidomide derivatives including lenalidomide and pomalidomide. The molecule that caused one of pharma's worst disasters is a significant commercial asset for Indian manufacturers today.
The thalidomide tragedy did not happen because science failed. It happened because nobody made asking "what does this do to a fetus?" mandatory before launch. Every preclinical testing requirement that exists in pharma today — teratogenicity studies, multi-generational reproductive toxicology, mandatory efficacy data — is a direct consequence of this case. The question was always askable. It just was not required.
What this means for your career
The thalidomide case is not a story about one bad drug or one negligent company. It is a story about what happens when the regulatory framework does not ask the right questions before a drug reaches patients. The entire preclinical testing structure that every pharma professional works within today exists because this gap was exposed at enormous human cost.
It is also a story about regulatory courage. Frances Kelsey did not have better data than the Europeans. She had higher standards for what data she would accept. That difference saved thousands. In a career in regulatory affairs, drug safety, or clinical development, you will face pressure to accept incomplete data and move faster. Kelsey's decision is the professional benchmark.
And the Indian chapter teaches something specific: regulatory gaps do not disappear just because the main market is protected. They migrate to wherever the oversight is weakest. Goa in 1959. The leprosy clinic networks in 1966. Understanding where the gaps are — and why they exist — is part of what it means to work in this industry seriously.
The next case study worth reading is on Ranbaxy and the FDA — a more recent story about what happens when quality data is falsified inside a system built on trust.